iBio (IBIO) surges due to update on COVID-19 vaccine development
iBio Inc (IBIO) currently trades at $0.94 and has grown by 7.14% today. IBIO went up $0.06 from the previous closing price of $0.88. The high forecast for iBio Inc is $30.00 and the low is $3.00. The company’s market cap is $94.97 million with a 52 week high of $3.40 and a 52 week low of $0.05. IBIO has changed in price by 0.12 per share in the last 12 months. iBio announced hat it has inked two Master Services Agreements and a Memorandum of Understanding (MoU) with the Infectious Disease Research Institute (IDRI) aimed at advancing its SARS-CoV-2 Virus-Like Particle vaccine candidate. The MoU calls for a separate agreement within 60 days between the parties if the company opts to include one of IDRI’s adjuvants in the program (called IBIO-200).
iBio Inc has a weak EPS of -1.58. This means the company lost $-1.58 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article.
About iBio Inc:
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.